First...Newsletter = no pattern.
January 7, 2020 1Q2020 Newsletter was released.
One year later on February 1,2021 1Q2021 was released (+23 days).
2Q2020 = 21 April 2020...
2Q2021 = 27 April 2021 (+6 days).
3Q2020 = 17 August 2020...
3Q2021 = 30 August 2021 (+13 days).
4Q2020 = 26 October 2020...
4Q2021 = 29 November 2021 (+32 days).
No precise pattern, TLT release the Newsletter when management is satisfied with the compiled numbers.
Worst case scenario...
In the last Newsletter 3Q2021...
https://theralase.com/wp-content/uploads/2021/11/3Q-2021-Newsletter.pdf Page 5...TLT said " In the total population of 33 patients (90 days), the potential for CR(complete response) is up to 75.8% ".
-Those 33 patients include the 12 undertreated patients (patients that did not receive the proper dosage of TLD 1433).
If the 75.8%CR include the 12 undertreated patients, you can bet your shirt that the optimized patients ( patients that did receive the proper dosage of TLD 1433) CR% can only go up and be over 75.8%CR.
Because of the immune response the same CR% will continue to be at 180, 270, 365 days.
The FDA is aware that the optimized patients CR% will be the number to watch for....But nevertheless if in the next Newsletter a CR% over 70% for the first 33 patients (including the 12 undertreated) could be enough to prompt the FDA to give TLT treatment BTD (Break Through Designation).
With 12 patients undertreated out of 33 patients, over 70%CR would be exceptionally good, considering that TLT cancer treatment target only patients that do not respond to BCG treatment.
In these time of market instability the SP is irrelevant, most TLT investors are holding on to there precious TLT shares.
Investors seem to have come to the conclusion that a CR% over 75% - 80% could be childplay for the optimized patients.
All the above make it much easier to hold on to ours TLT shares and wait for the next Newsletter CR%.